108 related articles for article (PubMed ID: 15033547)
1. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Toxicology; 2004 May; 197(3):253-61. PubMed ID: 15033547
[TBL] [Abstract][Full Text] [Related]
2. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Chem Biol Interact; 2003 Feb; 143-144():459-68. PubMed ID: 12604232
[TBL] [Abstract][Full Text] [Related]
3. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
Skarydová L; Skarka A; Novotná R; Zivná L; Martin HJ; Wsól V; Maser E
Toxicology; 2009 Oct; 264(1-2):52-60. PubMed ID: 19635524
[TBL] [Abstract][Full Text] [Related]
4. Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues.
Szotáková B; Skálová L; Jílek P; Buchta V; Wsól V
J Pharm Pharmacol; 2003 Jul; 55(7):1003-11. PubMed ID: 12906758
[TBL] [Abstract][Full Text] [Related]
5. A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig.
Skálová L; Wsól V; Szotáková B; Kvasnicková E
Chirality; 1999; 11(5-6):510-5. PubMed ID: 10368925
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
7. Reduction of the potential anticancer drug oracin in the rat liver in-vitro.
Szotáková B; Skálová L; Wsól V; Kvasniècková E
J Pharm Pharmacol; 2000 May; 52(5):495-500. PubMed ID: 10864136
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo.
Wsól V; Skálová L; Szotáková B; Trejtnar F; Kvasnicková E
Chirality; 1999; 11(5-6):505-9. PubMed ID: 10368924
[TBL] [Abstract][Full Text] [Related]
9. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin.
Wsól V; Szotáková B; Skálová L; Cepková H; Kvasnicková E
Enantiomer; 2000; 5(3-4):263-70. PubMed ID: 11126866
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Novotna R; Wsol V; Xiong G; Maser E
Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective carbonyl reduction of eperisone in human liver microsomes.
Yoo HH; Kim NS; Kim MJ; Shin D; Shin JG; Kim DH
Xenobiotica; 2011 Sep; 41(9):758-63. PubMed ID: 21623702
[TBL] [Abstract][Full Text] [Related]
12. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
13. Role of cytochrome P4501A in biotransformation of the potential anticancer drug oracin.
Szotáková B; Wsól V; Skálová L; Kvasnicková E
Exp Toxicol Pathol; 1999 Jul; 51(4-5):428-31. PubMed ID: 10445410
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison.
Wsól V; Szotáková B; Kvasnicková E; Fell AF
J Chromatogr A; 1998 Feb; 797(1-2):197-201. PubMed ID: 9542111
[TBL] [Abstract][Full Text] [Related]
15. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
Desbriere R; Vuaroqueaux V; Achard V; Boullu-Ciocca S; Labuhn M; Dutour A; Grino M
Obesity (Silver Spring); 2006 May; 14(5):794-8. PubMed ID: 16855188
[TBL] [Abstract][Full Text] [Related]
16. 11Beta hydroxysteroid dehydrogenase type 1 is expressed and is biologically active in human skeletal muscle.
Jang C; Obeyesekere VR; Dilley RJ; Alford FP; Inder WJ
Clin Endocrinol (Oxf); 2006 Dec; 65(6):800-5. PubMed ID: 17121533
[TBL] [Abstract][Full Text] [Related]
17. An in vitro microdialysis methodology to study 11beta-hydroxysteroid dehydrogenase type 1 enzyme activity in liver microsomes.
Sun L; Stenken JA; Yang AY; Zhao JJ; Musson DG
Anal Biochem; 2007 Nov; 370(1):26-37. PubMed ID: 17765862
[TBL] [Abstract][Full Text] [Related]
18. Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily.
Skarydová L; Wsól V
Drug Metab Rev; 2012 May; 44(2):173-91. PubMed ID: 22181347
[TBL] [Abstract][Full Text] [Related]
19. Cooperativity between 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase is based on a common pyridine nucleotide pool in the lumen of the endoplasmic reticulum.
Czegle I; Piccirella S; Senesi S; Csala M; Mandl J; Bánhegyi G; Fulceri R; Benedetti A
Mol Cell Endocrinol; 2006 Mar; 248(1-2):24-5. PubMed ID: 16337333
[TBL] [Abstract][Full Text] [Related]
20. 11Beta-hydroxysteroid dehydrogenase type 1: purification from human liver and characterization as carbonyl reductase of xenobiotics.
Maser E; Wsol V; Martin HJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):34-7. PubMed ID: 16343739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
